{"id":1895,"date":"2025-02-18T02:58:27","date_gmt":"2025-02-18T02:58:27","guid":{"rendered":"http:\/\/kinesciences.net\/?page_id=1895"},"modified":"2025-02-26T02:13:05","modified_gmt":"2025-02-26T02:13:05","slug":"%ed%8c%8c%ec%9d%b4%ed%94%84%eb%9d%bc%ec%9d%b8","status":"publish","type":"page","link":"https:\/\/kinesciences.net\/?page_id=1895&lang=ko","title":{"rendered":"\ud30c\uc774\ud504\ub77c\uc778"},"content":{"rendered":"<style>.kb-row-layout-id1895_6a89fb-e5 > .kt-row-column-wrap{align-content:start;}:where(.kb-row-layout-id1895_6a89fb-e5 > .kt-row-column-wrap) > .wp-block-kadence-column{justify-content:start;}.kb-row-layout-id1895_6a89fb-e5 > .kt-row-column-wrap{column-gap:var(--global-kb-gap-md, 2rem);row-gap:var(--global-kb-gap-md, 2rem);max-width:var( --global-content-width, 1290px );padding-left:var(--global-content-edge-padding);padding-right:var(--global-content-edge-padding);padding-top:320px;padding-right:20px;padding-bottom:140px;padding-left:20px;grid-template-columns:minmax(0, 1fr);}.kb-row-layout-id1895_6a89fb-e5{background-image:url('http:\/\/kinesciences.net\/wp-content\/uploads\/2025\/02\/image-11.png');background-size:cover;background-position:48% 57.99999999999999%;background-attachment:scroll;background-repeat:no-repeat;}.kb-row-layout-id1895_6a89fb-e5 > .kt-row-layout-overlay{opacity:0.55;background-color:var(--global-palette3, #1A202C);mix-blend-mode:normal;}@media all and (max-width: 1024px){.kb-row-layout-id1895_6a89fb-e5 > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}@media all and (max-width: 767px){.kb-row-layout-id1895_6a89fb-e5 > .kt-row-column-wrap{padding-top:var(--global-kb-spacing-xxl, 5rem);grid-template-columns:minmax(0, 1fr);}}<\/style><div class=\"kb-row-layout-wrap kb-row-layout-id1895_6a89fb-e5 alignnone kt-row-has-bg wp-block-kadence-rowlayout\"><div class=\"kt-row-layout-overlay kt-row-overlay-normal\"><\/div><div class=\"kt-row-column-wrap kt-has-1-columns kt-row-layout-equal kt-tab-layout-inherit kt-mobile-layout-row kt-row-valign-top kb-theme-content-width\">\n<style>.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col,.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col:before{border-top-left-radius:0px;border-top-right-radius:0px;border-bottom-right-radius:0px;border-bottom-left-radius:0px;}.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col{column-gap:var(--global-kb-gap-sm, 1rem);}.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col{flex-direction:column;}.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col > .aligncenter{width:100%;}.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col:before{opacity:0.3;}.kadence-column1895_c1dd67-a0{position:relative;}@media all and (max-width: 1024px){.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col{flex-direction:column;}}@media all and (max-width: 767px){.kadence-column1895_c1dd67-a0 > .kt-inside-inner-col{flex-direction:column;}}<\/style>\n<div class=\"wp-block-kadence-column kadence-column1895_c1dd67-a0 inner-column-1\"><div class=\"kt-inside-inner-col\"><style>.wp-block-kadence-advancedheading.kt-adv-heading1895_8492e9-05, .wp-block-kadence-advancedheading.kt-adv-heading1895_8492e9-05[data-kb-block=\"kb-adv-heading1895_8492e9-05\"]{margin-top:0px;text-align:center;font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading1895_8492e9-05 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading1895_8492e9-05[data-kb-block=\"kb-adv-heading1895_8492e9-05\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}<\/style>\n<h2 class=\"kt-adv-heading1895_8492e9-05 wp-block-kadence-advancedheading has-theme-palette-9-color has-text-color\" data-kb-block=\"kb-adv-heading1895_8492e9-05\"><strong>Pipeline<\/strong><\/h2>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-1895_4c5848-86 .kt-block-spacer{height:6px;}.wp-block-kadence-spacer.kt-block-spacer-1895_4c5848-86 .kt-divider{border-top-width:1px;height:1px;border-top-color:var(--global-palette2, #2B6CB0);width:50%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-1895_4c5848-86\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\"\/><\/div><\/div>\n\n\n<style>.wp-block-kadence-advancedheading.kt-adv-heading1895_29f824-32, .wp-block-kadence-advancedheading.kt-adv-heading1895_29f824-32[data-kb-block=\"kb-adv-heading1895_29f824-32\"]{text-align:center;font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading1895_29f824-32 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading1895_29f824-32[data-kb-block=\"kb-adv-heading1895_29f824-32\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}<\/style>\n<p class=\"kt-adv-heading1895_29f824-32 wp-block-kadence-advancedheading has-theme-palette-9-color has-text-color\" data-kb-block=\"kb-adv-heading1895_29f824-32\">.<\/p>\n<\/div><\/div>\n\n<\/div><\/div>\n\n<style>.kb-row-layout-id1895_3638b2-40 > .kt-row-column-wrap{align-content:start;}:where(.kb-row-layout-id1895_3638b2-40 > .kt-row-column-wrap) > .wp-block-kadence-column{justify-content:start;}.kb-row-layout-id1895_3638b2-40 > .kt-row-column-wrap{column-gap:var(--global-kb-gap-md, 2rem);row-gap:var(--global-kb-gap-md, 2rem);max-width:1306px;margin-left:auto;margin-right:auto;padding-top:var(--global-kb-spacing-sm, 1.5rem);padding-bottom:var(--global-kb-spacing-5xl, 10rem);grid-template-columns:minmax(0, 1fr);}.kb-row-layout-id1895_3638b2-40 > .kt-row-layout-overlay{opacity:0.30;}@media all and (max-width: 1024px){.kb-row-layout-id1895_3638b2-40 > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}@media all and (max-width: 767px){.kb-row-layout-id1895_3638b2-40 > .kt-row-column-wrap{grid-template-columns:minmax(0, 1fr);}}<\/style><div class=\"kb-row-layout-wrap kb-row-layout-id1895_3638b2-40 alignnone has-theme-palette7-background-color kt-row-has-bg wp-block-kadence-rowlayout\"><div class=\"kt-row-column-wrap kt-has-1-columns kt-row-layout-equal kt-tab-layout-inherit kt-mobile-layout-row kt-row-valign-top\">\n<style>.kadence-column1895_2d5506-5d > .kt-inside-inner-col,.kadence-column1895_2d5506-5d > .kt-inside-inner-col:before{border-top-left-radius:0px;border-top-right-radius:0px;border-bottom-right-radius:0px;border-bottom-left-radius:0px;}.kadence-column1895_2d5506-5d > .kt-inside-inner-col{column-gap:var(--global-kb-gap-sm, 1rem);}.kadence-column1895_2d5506-5d > .kt-inside-inner-col{flex-direction:column;}.kadence-column1895_2d5506-5d > .kt-inside-inner-col > .aligncenter{width:100%;}.kadence-column1895_2d5506-5d > .kt-inside-inner-col:before{opacity:0.3;}.kadence-column1895_2d5506-5d{position:relative;}@media all and (max-width: 1024px){.kadence-column1895_2d5506-5d > .kt-inside-inner-col{flex-direction:column;}}@media all and (max-width: 767px){.kadence-column1895_2d5506-5d > .kt-inside-inner-col{flex-direction:column;}}<\/style>\n<div class=\"wp-block-kadence-column kadence-column1895_2d5506-5d\"><div class=\"kt-inside-inner-col\">\n<!DOCTYPE html>\n<html>\n<head>\n    <meta charset=\"UTF-8\">\n    <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n    <title>Pipeline Dashboard<\/title>\n\n<style>\n* {\n    margin: 0;\n    padding: 0;\n    box-sizing: border-box;\n    -webkit-font-smoothing: antialiased;\n    -moz-osx-font-smoothing: grayscale;\n}\n\nbody {\n    font-family: -apple-system, BlinkMacSystemFont, 'SF Pro Text', 'Helvetica Neue', sans-serif;\n    line-height: 1.47059;\n    color: #1d1d1f;\n    background: #f5f5f7;\n    padding: 20px;\n}\n\n\n\nbody.page, \nbody.single, \nbody.archive, \nbody.blog, \nbody.wp-custom-logo, \nbody.page-template-default {\n    margin: 0 !important;\n    padding: 0 !important;\n    overflow-x: hidden;\n}\n\n\n\/* Enhanced Table styling *\/\ntable {\n    width: 100%;\n    border-collapse: separate;\n    border-spacing: 0;\n    background: #ffffff;\n    border-radius: 5px;\n    overflow: hidden;\n    box-shadow: 0 8px 32px rgba(0,0,0,0.06);\n    margin: 20px 0;\n    border: 1px solid rgba(0,0,0,0.04);\n}\n\n\/* Sophisticated header styling *\/\nth {\n    background: linear-gradient(180deg, #ffffff 0%, #f7f7f7 100%);\n    font-weight: 600;\n    color: #1d1d1f;\n    text-transform: capitalize;\n    padding: 20px 16px;\n    font-size: 15px;\n    letter-spacing: -0.01em;\n    border-bottom: 1px solid rgba(0,0,0,0.08);\n    position: relative;\n}\n\nth:after {\n    content: '';\n    position: absolute;\n    bottom: 0;\n    left: 0;\n    right: 0;\n    height: 1px;\n    background: linear-gradient(90deg, rgba(0,0,0,0.04) 0%, rgba(0,0,0,0.08) 50%, rgba(0,0,0,0.04) 100%);\n}\n\ntd {\n    padding: 16px;\n    text-align: left;\n    border-bottom: 1px solid rgba(0,0,0,0.04);\n    font-size: 14px;\n    color: #1d1d1f;\n    background: #ffffff;\n}\n\n\/* Disease area styling with iOS-like border *\/\n.disease-area {\n    color: #06c;\n    font-weight: 600;\n    border: 2px solid #6969e4 !important;\n    background: rgba(105,105,228,0.03);\n    border-radius: 4px;\n}\n\n\/* Progress bar styling *\/\n.pipeline-progress {\n    height: 8px;\n    background: #e8e8ed;\n    border-radius: 6px;\n    position: relative;\n    width: 100%;\n    overflow: hidden;\n    box-shadow: inset 0 1px 2px rgba(0,0,0,0.05);\n}\n\n.progress-bar {\n    height: 100%;\n    background: linear-gradient(90deg, #06c 0%, #0077ed 100%);\n    border-radius: 6px;\n    position: absolute;\n    left: 0;\n    transition: width 0.5s cubic-bezier(0.4, 0.0, 0.2, 1);\n}\n\n.progress-bar.light {\n    background: linear-gradient(90deg, #2997ff 0%, #47a3ff 100%);\n}\n\n\/* Enhanced Project button styling *\/\n.project-button {\n    background: none;\n    border: none;\n    color: #06c;\n    cursor: pointer;\n    display: inline-flex;\n    align-items: center;\n    gap: 8px;\n    padding: 8px 12px;\n    font-size: 14px;\n    position: relative;\n    transition: all 0.2s ease;\n    border-radius: 8px;\n}\n\n.project-button:hover {\n    color: #0077ed;\n    background: rgba(0,102,204,0.05);\n}\n\n.project-button span {\n    width: 22px;\n    height: 22px;\n    background: linear-gradient(135deg, #06c 0%, #0077ed 100%);\n    border-radius: 50%;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    color: white;\n    font-size: 12px;\n    transition: all 0.2s ease;\n    box-shadow: 0 2px 4px rgba(0,102,204,0.2);\n}\n\n.project-button:hover span {\n    background: linear-gradient(135deg, #0077ed 0%, #0088ff 100%);\n    transform: translateX(2px);\n}\n\n\/* Subtext styling *\/\n.subtext {\n    color: #86868b;\n    font-size: 12px;\n    display: block;\n    margin-top: 4px;\n    font-weight: normal;\n    letter-spacing: -0.01em;\n}\n\n\/* Enhanced popup styling *\/\n.popup {\n    display: none;\n    position: fixed;\n    top: 50%;\n    left: 50%;\n    transform: translate(-50%, -50%);\n    background: rgba(255, 255, 255, 0.98);\n    padding: 32px;\n    border-radius: 24px;\n    box-shadow: 0 20px 40px rgba(0,0,0,0.15), 0 0 0 1px rgba(0,0,0,0.04);\n    z-index: 1000;\n    max-width: 580px;\n    width: 90%;\n    backdrop-filter: blur(20px);\n    -webkit-backdrop-filter: blur(20px);\n}\n\n.popup-header {\n    margin-bottom: 24px;\n}\n\n.popup-title {\n    color: #1d1d1f;\n    font-size: 24px;\n    font-weight: 600;\n    margin-bottom: 8px;\n    letter-spacing: -0.02em;\n    line-height: 1.2;\n}\n\n.popup-subtitle {\n    color: #86868b;\n    font-size: 16px;\n    font-weight: 400;\n    letter-spacing: -0.01em;\n    line-height: 1.4;\n    margin-bottom: 16px;\n}\n\n.popup-content {\n    margin-bottom: 24px;\n}\n\n.popup-textarea {\n    width: 100%;\n    min-height: 140px;\n    padding: 16px;\n    border: none;\n    border-radius: 14px;\n    font-family: -apple-system, BlinkMacSystemFont, 'SF Pro Text', 'Helvetica Neue', sans-serif;\n    font-size: 15px;\n    line-height: 1.5;\n    color: #1d1d1f;\n    background: #f5f5f7;\n    resize: none;\n    margin-bottom: 24px;\n    transition: background-color 0.2s ease;\n}\n\n.popup-footer {\n    text-align: right;\n}\n\n.close-button {\n    background: #06c;\n    color: white;\n    border: none;\n    padding: 12px 28px;\n    border-radius: 980px;\n    cursor: pointer;\n    font-size: 15px;\n    font-weight: 500;\n    transition: all 0.2s ease;\n    letter-spacing: -0.01em;\n    box-shadow: 0 2px 6px rgba(0,102,204,0.2);\n}\n\n.close-button:hover {\n    background: #0077ed;\n    transform: scale(1.02);\n    box-shadow: 0 4px 12px rgba(0,102,204,0.3);\n}\n\n.close-button:active {\n    transform: scale(0.98);\n    box-shadow: 0 2px 4px rgba(0,102,204,0.2);\n}\n\n\/* Enhanced overlay styling *\/\n.overlay {\n    display: none;\n    position: fixed;\n    top: 0;\n    left: 0;\n    width: 100%;\n    height: 100%;\n    background: rgba(0,0,0,0.4);\n    backdrop-filter: blur(8px);\n    -webkit-backdrop-filter: blur(8px);\n    z-index: 999;\n    transition: opacity 0.3s ease;\n}\n\n\/* Responsive adjustments for popup *\/\n@media screen and (max-width: 1068px) {\n    .popup {\n        padding: 28px;\n        max-width: 520px;\n    }\n    \n    .popup-title {\n        font-size: 22px;\n    }\n    \n    .popup-subtitle {\n        font-size: 15px;\n    }\n    \n    .popup-textarea {\n        font-size: 14px;\n        min-height: 120px;\n    }\n}\n\n@media screen and (max-width: 734px) {\n    .popup {\n        padding: 24px;\n        width: 95%;\n        border-radius: 20px;\n    }\n    \n    .popup-title {\n        font-size: 20px;\n    }\n    \n    .popup-subtitle {\n        font-size: 14px;\n    }\n    \n    .popup-textarea {\n        padding: 14px;\n        font-size: 14px;\n        min-height: 100px;\n        border-radius: 12px;\n    }\n    \n    .close-button {\n        padding: 10px 24px;\n        font-size: 14px;\n    }\n}\n\n\n<\/style>\n\n<\/head>\n<body>\n    <!-- Common Overlay and Popup -->\n    <div id=\"overlay\" class=\"overlay\"><\/div>\n   <div id=\"overlay\" class=\"overlay\"><\/div>\n    <div id=\"commonPopup\" class=\"popup\">\n        <div class=\"popup-header\">\n            <h3 id=\"popupTitle\" class=\"popup-title\"><\/h3>\n            <h4 id=\"popupSubtitle\" class=\"popup-subtitle\"><\/h4>\n        <\/div>\n        <div class=\"popup-content\">\n <textarea id=\"popupRemark\" rows=\"4\" readonly class=\"popup-textarea\"><\/textarea>\n        <\/div>\n        <div class=\"popup-footer\">\n            <button class=\"close-button\" onclick=\"hidePopup()\">Close<\/button>\n        <\/div>\n    <\/div>\n\n    <!-- Main Table -->\n    <table>\n        <thead>\n            <tr>\n                <th>Disease Area<\/th>\n                <th>Indication<\/th>\n                <th>Project<\/th>\n                <th>Target Cell<\/th>\n                <th>Discovery<\/th>\n                <th>Preclinical<\/th>\n                <th>Phase 1<\/th>\n                <th>Phase 1b\/2a<\/th>\n            <\/tr>\n        <\/thead>\n        <tbody>\n            <tr>\n                <td class=\"disease-area\">PNS<br><span class=\"subtext\">(Peripheral nervous system)<\/span><\/td>\n                <td>CIDP<br><span class=\"subtext\">(Chronic Inflammatory Demyelinating Polyradiculoneuropathy)<\/span><\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-101C\"\n                    data-subtitle=\"\ub9cc\uc131\uc5fc\uc99d\uc131 \ud0c8\uc218\ucd08 \ub2e4\ubc1c\uc2e0\uacbd\ubcd1\uc99d(CIDP\"\n                    data-description=\"\ub9cc\uc131\uc5fc\uc99d\uc131 \ud0c8\uc218\ucd08 \ub2e4\ubc1c\uc2e0\uacbd\ubcd1\uc99d (Chronic Inflammatory Demyelinating Polyneuropathy:  CIDP)\uc740 \uba74\uc5ed\uc138\ud3ec\ub4e4\uc774 \ub9d0\ucd08\uc2e0\uacbd\uc758 \uc218\ucd08(\ud53c\ub9c9)\ub97c \uacf5\uaca9\ud574 \ubc1c\uc0dd\ud558\ub294 \uc790\uac00\uba74\uc5ed\uc9c8\ud658\uc758 \ud558\ub098\ub85c \uc2e0\uacbd \uc2e0\ud638 \uc804\ub2ec\uc5d0 \ud544\uc218\uc801\uc778 \uc218\ucd08\uac00 \uc190\uc0c1\ub418\uba74 \ud314\ub2e4\ub9ac \ud798 \ube60\uc9d0\uacfc \uac10\uac01 \uc774\uc0c1\uc774 \ub098\ud0c0\ub098\uba70, \uc774\ub85c \uc778\ud574 \uac77\uae30 \uc5b4\ub824\uc6cc\uc9c0\uac70\ub098 \uade0\ud615\uc744 \uc783\ub294 \uc99d\uc0c1\uc774 \ubc1c\uc0dd\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.\n \n\ub9cc\uc131 \uc5fc\uc99d\uc131 \ud0c8\uc218\ucd08 \ub2e4\ubc1c\uc2e0\uacbd\ubcd1\uc99d\uc740 \uc57d\ubb3c\uc758 \uc7a5\uae30 \ud22c\uc5ec\uac00 \uc694\uad6c\ub418\ub294 \ub9cc\uc131\uc790\uac00\uba74\uc5ed\uc9c8\ud658\uc73c\ub85c \uae30\uc804 \ud2b9\uc774\uc801\uc774\uba70 \uc548\uc804\ud55c \uce58\ub8cc\uc81c \uac1c\ubc1c\uc774 \ud544\uc694\ud55c \uc0c1\ud669\uc785\ub2c8\ub2e4. \n\ub2e4\uc591\ud55c CIDP \ub3d9\ubb3c\ubaa8\ub378\uc5d0\uc11c Treg \uc138\ud3ec \ud65c\uc131\ud654\ub97c \ud1b5\ud55c KINE-101 \uae30\uc804 \ud2b9\uc774\uc801\uc778 \uc9c8\ud658 \uac1c\uc120 \ud6a8\ub2a5\uc744 \ud655\uc778\ud558\uc600\uc2b5\ub2c8\ub2e4. (KINE-101\uc740 Treg  activator\ub85c, \ud56d\uc6d0\uc81c\uc2dc\uc138\ud3ec(APC) \uc5b5\uc81c, \uc5fc\uc99d \ubc18\uc751 \ubc0f \uc790\uac00\ud56d\uccb4 \uc0dd\uc131\uc744 \uac10\uc18c\uc2dc\ud0b4)\n\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-101C <span>&gt;<\/span>\n                <\/button>\n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar\" style=\"width: 95%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td rowspan=\"2\" class=\"disease-area\">Autoimmune<\/td>\n                <td>RA<br><span class=\"subtext\">(Rheumatoid Arthritis)<\/span><\/td>\n                <td>\n                    \n                    \n                    \n                    <button class=\"project-button\"\n                    data-title=\"KINE-101A\"\n                    data-subtitle=\"for Rheumatoid arthritis (RA)\"\n                    data-description=\"RA is a representative autoimmune disease accompanied with severe pain and dysfunction of joints. Largely 1% of global population suffer from RA and RA is the biggest autoimmune diseases at present. Despite recent launches of new drugs for RA, most drugs have problems of toxicity and drug resistance when they are administered in the long-term. Therefore, there are unmet medical needs for drugs of novel mode of action and long-term safety.\n                \n                KINE-101A is a synthetic peptide consisting of 9 amino acids. By selectively activating Treg cells it reduces production of pro-inflammatory cytokines, decreases formation of anti-drug antibodies, and restores balances between disease-causing T cells and Treg cells. Currently, KINE-101A was completed for Phase 1 in US FDA. In addition, KINE-101A also developing on oral therapy as new oral therapeutic option for Rheumatoid arthritis.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-101A <span>&gt;<\/span>\n                <\/button>\n                \n                    \n                    \n                    \n                <\/td>\n                <td>Treg<\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar\" style=\"width: 80%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>IBD<br><span class=\"subtext\">(Inflammatory Bowel Disease)<\/span><\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-101B\"\n                    data-subtitle=\"for Inflammatory bowel disease (IBD)\"\n                    data-description=\"Two major diseases of IBD are Crohn\u2019s disease and ulcerative colitis. \n                Though underlying causes of these diseases have yet to be found, abnormal intestinal immunity is thought to bring about excessive inflammation in the gut. Symptoms are abdominal pain, frequent diarrhea and fever, which severely hurts patients\u2019 quality of life. Since largely 50% of patients do not respond to current treatments, development of drugs of novel mechanism are much needed.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-101B <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 50%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td class=\"disease-area\">Metabolite<\/td>\n                <td>NASH<br><span class=\"subtext\">(Non-Alcoholic Steatohepatitis)<\/span><\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-101D\"\n                    data-subtitle=\"for Non-Alcoholic Steatohepatitis (NASH)\"\n                    data-description=\"NASH is a representative disease of NAFLD, characterized by the presence of more than 5% fat accumulation (steatosis) in hepatocytes and inflammation (ballooning) accompanied by hepatocellular damage with or without fibrosis.\n                NASH doesn\u2019t only include simple liver steatosis, but also inflammation and damage to the liver. However, there is no treatment available for NASH, and most research and development are failing in the clinical stage.\n                But, in a previous study, we found KINE-101 treatment showed possibility of improvement for NASH. First, KINE-101 inhibited lipid accumulation and cholesterol. Second, KINE-101 alleviate the abnormal liver enzyme activity and liver index. In addition, KINE-101 inhibited the increase of fibrosis caused by inflammatory cytokines. Currently, we are researching the efficacy and the mechanism of KINE-101 in a NASH animal model.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-101D <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 45%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td class=\"disease-area\">Dermatology<\/td>\n                <td>Atopic dermatitis<\/td>\n                <td>\n                    <button class=\"project-button\"\n    data-title=\"KINE-201A\"\n    data-subtitle=\"for Atopic dermatitis (AD)\"\n    data-description=\"AD is an inflammatory dermatological disorder prevalent both in children and adults.\nPatients of AD have comorbidities such as asthma and allergic rhinitis and AD is known to be caused by various allergens like pyroglyphidae.\nRepresentative symptom of AD is severe itchiness that disturbs sleep and tends to become chronic and recur.\nAnti-histamines, non-steroidal anti-inflammatory drug (NSAID), and oral steroids have been used and monoclonal antibody drugs are very recently launched. Given the chronic, recurring nature of AD, drugs of novel mode of action with superior long-term safety are much needed.\nKINE-201 inhibits production of TSLP and regulates function of disease-causing T cells. KINE-201 proves its efficacy in animal studies and is currently under GLP studies.\"\n    onclick=\"handleProjectClick(this)\">\n    KINE-201A <span>&gt;<\/span>\n<\/button>\n\n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 48%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td rowspan=\"2\" class=\"disease-area\">Respiratory<\/td>\n                <td>Asthma<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-201B\"\n                    data-subtitle=\"for Asthma\"\n                    data-description=\"Asthma is a chronic inflammatory disease of lung airways with symptoms of coughing, airflow obstruction, and immoderate production of mucus. And T helper 2 (Th2) cells are well known to be related with the cause, pathogenesis, and severity of the disease. \n                For treatments, corticosteroids and immune suppressants have been used, but, because of their side effects and high cost, there exist unmet needs for novel drug development for asthma.\n                KINE-201 is a novel therapeutic candidate for asthma as an inhibitor of Th2 responses. Currently, KINE-201B is on the non-clinical stage and we are performing in vivo studies.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-201B <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td>Th2<\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 45%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>COPD\n<br><span class=\"subtext\">(Chronic Obstructive Pulmonary Disease)<\/span><\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-201C\"\n                    data-subtitle=\"\ub9cc\uc131\ud3d0\uc1c4\uc131\ud3d0\uc9c8\ud658(COPD)\"\n                    data-description=\"\ub9cc\uc131 \ud3d0\uc1c4\uc131 \ud3d0\uc9c8\ud658\uc740 \uae30\uad00\uc9c0\uc640 \ud3d0 \uc870\uc9c1\uc5d0 \ub9cc\uc131\uc801\uc778 \uc5fc\uc99d\uc774 \ubc1c\uc0dd\ud558\ub294 \uc9c8\ud658\uc73c\ub85c \uae30\ub3c4 \ud3d0\uc0c9\uc5d0 \uc758\ud55c \ud638\ud761\uace4\ub780\uc744 \ud2b9\uc9d5\uc73c\ub85c \ud569\ub2c8\ub2e4.\u000b\ubbf8\uad6d\uc758 \uacbd\uc6b0 \uc57d 1,600\ub9cc \uba85\uc774 \uc9c4\ub2e8\ub418\uba70, \ub9e4\ub144 150,000\uba85 \uc774\uc0c1\uc774 \uc0ac\ub9dd. 2030\ub144\uae4c\uc9c0 \uc804\uc138\uacc4\uc5d0\uc11c 3\ubc88\uc9f8\ub85c \uc8fc\ub3c4\uc801\uc778 \uc0ac\ub9dd \uc6d0\uc778\uc774 \ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub9cc\uc131 \ud3d0\uc1c4\uc131 \ud3d0\uc9c8\ud658\uc740 \uacfc\ub3c4\ud55c Th2 \uc138\ud3ec \ubc18\uc751\uc5d0 \uc758\ud55c \uc9c8\ud658\uc758 \ubc1c\ub2ec \ubc0f \uc545\ud654\uac00 \ubcf4\uace0\ub41c \uc9c8\ud658\uc73c\ub85c  \ud604\uc7ac  \uc9c8\ud658\uc758 \ubc1c\ubcd1 \uae30\uc804\uc744 \uc9c1\uc811 \ud45c\uc801\ud558\ub294 \ucd08\uc18c\ud615 \uba74\uc5ed\uc870\uc808\uae30\ub2a5\uc131 \uc774\ubba8\ud3a9\ud0c0\uc774\ub4dc \uac1c\ubc1c\uc774 \ud544\uc694\ud568.\n\uc5fc\uc99d\uc131 \ud3d0\uc9c8\ud658\uc5d0\uc11c Th2 \uc138\ud3ec \ubc18\uc751\uc5d0 \uc758\ud574 \ud608\uc561\uc73c\ub85c\ubd80\ud130 \ud3d0\uc870\uc9c1\uc73c\ub85c eosinophil, neutrophil\uc758 \uc774\ub3d9\uc774 \uc99d\uac00\nKINE-201C\ub294 IL-4, IL-13, TSLP\ub97c \ud45c\uc801\uc73c\ub85c \ud558\uc5ec Th2 \ubc18\uc751\uc744 \uc5b5\uc81c\ud558\ub294 \uc9c8\ud658 \uac1c\uc120 \ud6a8\uacfc\ub97c \uac00\uc9c4 \ud6c4\ubcf4\ubb3c\uc9c8\ub85c KINE-201C\ub294 \ub9cc\uc131 \ud3d0\uc1c4\uc131 \ud3d0\uc9c8\ud658 \uce58\ub8cc\uc5d0\uc11c Th2 \uc138\ud3ec \uc5b5\uc81c\uc81c (Th2 cell inhibitor)\ub85c \uc791\uc6a9\ud569\ub2c8\ub2e4.\n\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-201C <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar\" style=\"width: 70%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td class=\"disease-area\">Dermatology<\/td>\n                <td>Psoriasis<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-301A\"\n                    data-subtitle=\"for Psoriasis\"\n                    data-description=\"Psoriasis is an inflammatory skin disease with symptoms of rash, itchy, dry, and scaly patches. Topical corticosteroids, methotrexate, and UV therapy have been used for psoriasis treatments, but they commonly show side effects and their mode of action is not psoriasis-specific.\n                Because T helper 17 (Th17) cells are the most critical factors to induce the pathogenesis of psoriasis, we are developing a psoriasis-specific drug KINE-301, which is a Th17 inhibitor. Currently, KINE-301A is in the late stage of discovery and we are preparing in vivo studies.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-301A <span>&gt;<\/span>\n                <\/button>\n                                   \n                <\/td>\n                <td>Th17<\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 45%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td class=\"disease-area\">Cancer<\/td>\n                <td>Solid tumor<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-401A\"\n                    data-subtitle=\"for Solid Tumor\"\n                    data-description=\"Cancer is a leading cause of death worldwide, and solid tumors account for 50% of childhood cancers and 90% of adult human cancers. However, there are no effective drugs available. NK (Natural Killer) cells have been suggested as a great treatment option for solid tumors. We are developing anti-cancer peptide drugs targeting NK cells to kill cancer cells for the treatment of solid tumors.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-401A <span>&gt;<\/span>\n                <\/button>\n                                \n                <\/td>\n                <td>NK<\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 15%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td rowspan=\"5\" class=\"disease-area\">CNS<br><span class=\"subtext\">(Central nervous system)<\/span><\/td>\n                <td>Alzheimer&#8217;s disease<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-501A\"\n                    data-subtitle=\"for Alzheimer\u2019s Disease\"\n                    data-description=\"Alzheimer\u2019s disease is a neurodegenerative disease where symptoms develop slowly over many years and eventually worsen. Alzheimer\u2019s disease causes memory loss, difficulties in thinking and problem-solving, and issues with language.\n                Recently, there have been concerns regarding clinical studies failing to meet their endpoints. Although some studies have shown a significant reduction in amyloid beta in Alzheimer\u2019s disease patients, they have not significantly slowed cognitive decline.\n                To address the unmet needs for Alzheimer\u2019s disease treatment, we have discovered an anti-inflammatory role of KINE-501 to reduce inflammatory mediators in the brain.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-501A <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 45%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>FTD<br><span class=\"subtext\">(Frontotemporal Dementia)<\/span><\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-501B\"\n                    data-subtitle=\"for Frontotemporal Dementia (FTD)\"\n                    data-description=\"Frontotemporal Dementia (FTD) is a rare brain disease occurring mostly between the ages of 45 and 65. Atrophy of the frontal and temporal lobes results in multiple cognitive disorders such as personality changes, apathy, or deficits in language.\n                Currently, only treatments that alleviate symptoms exist, but there is no known cure for FTD. The KINE-Peptide drug targets microglia to disrupt the accumulation of tau proteins and TAR DNA-binding protein 43 (TDP-43), which are considered common proteinopathies in FTD.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-501B <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 15%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>LBD<br><span class=\"subtext\">(Lewy Body Dementia)<\/span><\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-501C\"\n                    data-subtitle=\"for Lewy Body Dementia (LBD)\"\n                    data-description=\"Lewy Body Dementia (LBD) is characterized by cognitive disorders, movement problems (parkinsonian signs), or visual hallucinations. It is the second most common type of dementia after Alzheimer\u2019s disease.\n                Lewy bodies and Lewy neurites develop due to the aggregation of misfolded alpha-synuclein in cortical regions. Our aim is to develop peptide drugs that disrupt alpha-synuclein accumulation by modulating neuroinflammatory reactions.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-501C <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td>Microglial<\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 15%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>Parkinson&#8217;s disease<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-501D\"\n                    data-subtitle=\"for Parkinson's Disease\"\n                    data-description=\"Parkinson's disease shares similarities with Lewy Body Dementia. Lewy bodies and Lewy neurites are observed in Parkinson\u2019s disease patients, but they are mostly found in the subcortical basal ganglia.\n                The symptoms include involuntary shaking, slow movement, and cognitive impairments such as depression or memory problems. Our aim is to develop peptide drugs that disrupt alpha-synuclein accumulation by modulating neuroinflammatory reactions.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-501D <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 15%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>Multiple sclerosis<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-501E\"\n                    data-subtitle=\"for Multiple Sclerosis\"\n                    data-description=\"Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease that commonly causes non-traumatic disability in young adults.\n                Inducible nitric oxide synthase (iNOS) is an enzyme that produces nitric oxide (NO), an inflammatory factor secreted by microglia, contributing to the pathogenesis of MS. KINE-501E targets microglia to modulate iNOS expression and NO production, which are considered common mechanisms of action in MS.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-501E <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 15%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td rowspan=\"2\" class=\"disease-area\">Other<\/td>\n                <td>Wound healing<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-601A\"\n                    data-subtitle=\"for Wound Healing\"\n                    data-description=\"Intractable diabetic wounds, one of the representative chronic wounds, are accompanied by diabetic skin ulcers (DCU) and nerve ischemic ulcers. Each year, 50 to 70 percent of patients requiring amputation due to non-traumatic injuries are diabetic, experiencing high levels of depression and reduced quality of life.\n                Persistent hyperglycemia in diabetes patients can cause dysfunction of epithelial cells and vascular damage through decreased angiogenic signaling. Several candidate peptides of KINE-601B are regulators of wound healing, enhancing the production of VEGF and activating the Wnt\/\u03b2-catenin pathway, which is key to wound angiogenesis and epithelial re-epithelization. This peptide has demonstrated efficacy in animal studies using chronic diabetic wound models, providing an effective therapeutic approach for regenerative wound healing.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-601A <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td>Keratinocyte\/<br>Fibroblast<\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 45%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n            <tr>\n                <td>Alopecia<\/td>\n                <td>\n                    <button class=\"project-button\"\n                    data-title=\"KINE-601B\"\n                    data-subtitle=\"for Alopecia\"\n                    data-description=\"Alopecia areata (AA), a type of non-scarring hair loss, is an organ-specific autoimmune disease caused by T cell-mediated attacks against hair follicle autoantigens. Patients with severe AA experience poor quality of life, severe anxiety, and depression.\n                Historically, non-specific immunosuppressants were the mainstay of treatment for most AA patients. However, long-term administration of these treatments often leads to issues such as toxicity, inflammation, and immunosuppressive effects.\n                Recent advancements in AA research have highlighted the critical involvement of T helper 17 (Th17) cells and T regulatory (Treg) cells in the disease pathogenesis. Several KINE peptide candidates related to KINE-601A are being explored as alternative treatments targeting Th17 or Treg-specific mechanisms of action.\"\n                    onclick=\"handleProjectClick(this)\">\n                    KINE-601B <span>&gt;<\/span>\n                <\/button>\n                \n                <\/td>\n                <td><\/td>\n                <td colspan=\"4\">\n                    <div class=\"pipeline-progress\">\n                        <div class=\"progress-bar light\" style=\"width: 15%;\"><\/div>\n                    <\/div>\n                <\/td>\n            <\/tr>\n        <\/tbody>\n    <\/table>\n\n<br>\n<\/body>\n<\/html>\n\n\n<script>\n function showPopup(cTitle, cSubtitle, cRemark) {\n        const popup = document.getElementById('commonPopup');\n        const overlay = document.getElementById('overlay');\n        const titleElement = document.getElementById('popupTitle');\n        const subtitleElement = document.getElementById('popupSubtitle');\n        const remarkElement = document.getElementById('popupRemark');\n        \n        titleElement.textContent = cTitle;\n        subtitleElement.textContent = cSubtitle;\n        remarkElement.innerHTML = cRemark.replace(\/\\n\/g, '');\n        \n        popup.style.display = 'block';\n        overlay.style.display = 'block';\n        document.body.style.overflow = 'hidden';\n    }\n\n    function hidePopup() {\n        const popup = document.getElementById('commonPopup');\n        const overlay = document.getElementById('overlay');\n        \n        popup.style.display = 'none';\n        overlay.style.display = 'none';\n        document.body.style.overflow = 'auto';\n    }\n\n    document.addEventListener('DOMContentLoaded', function() {\n        const overlay = document.getElementById('overlay');\n        \n        overlay.addEventListener('click', hidePopup);\n\n        document.addEventListener('keydown', function(event) {\n            if (event.key === 'Escape') {\n                hidePopup();\n            }\n        });\n        \n        document.getElementById('commonPopup').addEventListener('click', function(event) {\n            event.stopPropagation();\n        });\n    });\n    \n    function handleProjectClick(button) {\n    const title = button.getAttribute(\"data-title\");\n    const subtitle = button.getAttribute(\"data-subtitle\");\n    const description = button.getAttribute(\"data-description\");\n\n    showPopup(title, subtitle, description);\n}\n    <\/script>\n<\/div><\/div>\n\n<\/div><\/div>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pipeline . Pipeline Dashboard Close Disease Area Indication Project Target Cell Discovery Preclinical Phase 1 Phase 1b\/2a PNS(Peripheral nervous system) CIDP(Chronic Inflammatory Demyelinating Polyradiculoneuropathy) KINE-101C &gt; Autoimmune RA(Rheumatoid Arthritis) KINE-101A &gt; Treg IBD(Inflammatory Bowel Disease) KINE-101B &gt; Metabolite NASH(Non-Alcoholic Steatohepatitis) KINE-101D &gt; Dermatology Atopic dermatitis KINE-201A &gt; Respiratory Asthma KINE-201B &gt; Th2 COPD (Chronic Obstructive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1397,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kadence_starter_templates_imported_post":true,"_kad_post_transparent":"default","_kad_post_title":"hide","_kad_post_layout":"fullwidth","_kad_post_sidebar_id":"","_kad_post_content_style":"unboxed","_kad_post_vertical_padding":"hide","_kad_post_feature":"hide","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"footnotes":""},"class_list":["post-1895","page","type-page","status-publish","has-post-thumbnail","hentry"],"lang":"ko","translations":{"ko":1895},"taxonomy_info":[],"featured_image_src_large":["https:\/\/kinesciences.net\/wp-content\/uploads\/2022\/01\/About-scaled-1-471x1024.jpeg",471,1024,true],"author_info":{"display_name":"admin","author_link":"https:\/\/kinesciences.net\/?author=1"},"comment_info":0,"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/pages\/1895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kinesciences.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1895"}],"version-history":[{"count":19,"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/pages\/1895\/revisions"}],"predecessor-version":[{"id":2282,"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/pages\/1895\/revisions\/2282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kinesciences.net\/index.php?rest_route=\/wp\/v2\/media\/1397"}],"wp:attachment":[{"href":"https:\/\/kinesciences.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}